Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

RARE PHOTOS: Biomarin pharmaceutical | Rare Historical Photos

Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings

Biomarin Pharmaceutical Inc (NASDAQ:BMRN) reported weaker-than-expected earnings for the third quarter on Monday.

Benzinga · Oct 28, 2025

2 'Strong Buy'-Rated Stocks That Could Rally 39% to 48% in 2025

Both of these growth stocks are positioned for long-term success.

Barchart · Oct 11, 2024

3 Biotech Stocks Beating BioMarin Pharmaceutical (BMRN)

Breakthrough developments, the use of advanced technologies, and rising investments in R&D are some of the factors driving the growth of the biotech industry. Although BioMarin Pharmaceutical (BMRN) showcases strong growth prospects, investors could consider buying even better biotech stocks Amgen (AMGN), Jazz Pharmaceuticals (JAZZ), and Vertex Pharmaceuticals (VRTX). Read…

StockNews.com · Nov 16, 2023

From analysis to the latest developments in health,
read the most diverse news in one place.

Widening tech, biotech job cuts could jolt broader Bay Area economy: experts

SAN JOSE, Calif. — Bay Area tech and biotech companies have recently revealed plans to chop thousands of jobs, layoffs that raise the specter that these cutbacks might haunt the region’s broader economy.

Tribune News Service · Nov 8, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022

Upgrades

Benzinga · Oct 31, 2022

Hundreds of tech and biotech layoffs rattle Bay Area job market

REDWOOD CITY, California — A tech titan and a biotech company revealed plans to chop nearly 300 jobs in the Bay Area, hinting at unsettling prospects for the region’s employment sector.

Tribune News Service · Oct 12, 2022

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients. BioMarin shares traded as high as 2.28 percent, in a range of $91.39 to $93.68…

Benzinga · Aug 24, 2022

Read news from The Economist, FT, and more,
with one subscription

What 4 Analyst Ratings Have To Say About Biomarin Pharmaceutical

Analysts have provided the following ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) within the last quarter:

Benzinga · Jun 13, 2022

Biomarin Pharmaceutical Earnings Preview

Biomarin Pharmaceutical (NASDAQ:BMRN) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Biomarin Pharmaceutical will report an earnings per share (EPS) of $0.17.

Benzinga · Apr 26, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022

Benzinga · Apr 25, 2022

A Bearish Sign Appears On Biomarin Pharmaceutical's Chart

If history is any guide, there may be trouble ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga · Apr 21, 2022

Recap: Biomarin Pharmaceutical Q4 Earnings

Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Biomarin Pharmaceutical reported in-line EPS of $-0.32 versus an estimate of $-0.32.

Benzinga · Feb 23, 2022

Coverage From

People

Dipanjan BanchurSince

722 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.